Testing the Short-Term Efficacy of a Lipid-Lowering Nutraceutical in the Setting of Clinical Practice: A Multicenter Study
Open Access
- 1 November 2015
- journal article
- research article
- Published by SAGE Publications in Journal of Medicinal Food
- Vol. 18 (11) , 1270-1273
Abstract
The main guidelines for cardiovascular disease prevention suggest that nutraceuticals could be an efficacious tool to improve lipid pattern. Our aim was to carry out a clinical trial comparing the metabolic effects of a combined nutraceutical containing both red yeast rice and polyunsaturated fatty acids (PUFAs) and a phytosterol-based approach in a setting of clinical practice. This was a multicenter open study with parallel control. We consecutively enrolled 107 pharmacologically untreated subjects affected by primary polygenic hypercholesterolemia and metabolic syndrome, assigned to 8-week treatment with a combined treatment with red yeast rice (Dif1Stat ® , including 5 mg monacolin K) and 610 mg PUFAs. A parallel group of 30 subjects with similar characteristics was treated with phytosterols 1600 mg/die. In the combined nutraceutical group, compared with the baseline level, we observed a significant decrease in total cholesterol (TC; −42.50 ± 18.1 mg/dL), low-density lipoprotein cholesterol (LDL-C; −37.6 ± 13.6 mg/dL), triglycerides (TG; −19.8 ± 25.1 mg/dL), and non-HDL-C (−43.1 ± 17.7 mg/dL) (all P < .001). In the phytosterol-treated group, compared to the baseline level, we observed a significant decrease in TC (−13.7 ± 4.3 mg/dL), LDL-C (−17.6 ± 8.5 mg/dL), and non-HDL-C (−14.1 ± 5.6 mg/dL) (all P < .001). When comparing the combined nutraceutical effect with that of phytosterols, we observed that the combined nutraceutical intake was associated with a significantly higher decrease in TC, LDL-C, TG, and non-HDL-C (all P < .001). In the short term, a combined nutraceutical containing red yeast rice and PUFAs is well tolerated and efficacious in reducing plasma lipid levels in subjects affected by primary polygenic hypercholesterolemia and metabolic syndrome.Keywords
This publication has 21 references indexed in Scilit:
- Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effectsExpert Opinion on Drug Safety, 2012
- Impact of healthy lifestyle on mortality in people with normal blood pressure, LDL cholesterol, and C-reactive proteinEuropean Journal of Preventive Cardiology, 2011
- Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA studyEuropean Heart Journal, 2011
- Economic Evaluation of Lifestyle Interventions for Preventing Diabetes and Cardiovascular DiseasesInternational Journal of Environmental Research and Public Health, 2010
- Gender-specific haemodynamic and metabolic effects of a sequential training programme on overweight-obese hypertensivesBlood Pressure, 2009
- Toward “Pain-Free” Statin Prescribing: Clinical Algorithm for Diagnosis and Management of MyalgiaMayo Clinic Proceedings, 2008
- Toward “Pain-Free” Statin Prescribing: Clinical Algorithm for Diagnosis and Management of MyalgiaMayo Clinic Proceedings, 2008
- Non-pharmacological control of plasma cholesterol levelsNutrition, Metabolism and Cardiovascular Diseases, 2008
- Antihyperlipidaemic effect of a Monascus purpureus brand dietary supplement on a large sample of subjects at low risk for cardiovascular disease: A pilot studyComplementary Therapies in Medicine, 2005
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001